Everence Capital Management Inc. Has $1.40 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Everence Capital Management Inc. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,940 shares of the medical research company’s stock after selling 2,040 shares during the quarter. Everence Capital Management Inc.’s holdings in Edwards Lifesciences were worth $1,402,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of EW. Wellington Management Group LLP grew its position in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after purchasing an additional 2,606,950 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares during the period. Worldquant Millennium Advisors LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $39,628,000. Finally, AustralianSuper Pty Ltd boosted its position in Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock worth $216,013,000 after buying an additional 494,604 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,500 shares of company stock worth $2,508,350 in the last quarter. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Up 1.8 %

NYSE EW opened at $73.91 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50 day moving average price of $70.99 and a 200-day moving average price of $72.83. The company has a market cap of $43.59 billion, a price-to-earnings ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business posted $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EW. Truist Financial restated a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Citigroup raised their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Stifel Nicolaus upped their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.